Literature DB >> 15934100

Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease.

Hilal Maradit Kremers1, Megan S Reinalda, Cynthia S Crowson, Alan R Zinsmeister, Gene G Hunder, Sherine E Gabriel.   

Abstract

OBJECTIVE: To describe the use of generalist and rheumatologist services in a population-based cohort of patients with polymyalgia rheumatica (PMR) and to identify predictors of rheumatology care.
METHODS: We identified all incident cases of PMR among residents of Olmsted County, Minnesota between 1970 and 1999. Patients were followed for a maximum of 5 years after their incidence date. Logistic regression and zero-inflated Poisson regression models were used to assess the association between rheumatology care and age, sex, giant cell arteritis (GCA), PMR relapses, corticosteroid complications, comorbidity, and various laboratory findings, adjusting for the total number of visits.
RESULTS: Of the 364 incident cases of PMR eligible for this analysis, 67% were women and the mean age at incidence was 73 years. Over a mean followup of 4.1 years, individuals in this cohort utilized a total of 5,108 physician office visits and 2,015 telephone calls. The mean number of generalist and rheumatologist visits per person-years of follow-up during the first year of PMR was 7.02 and 2.15, respectively. Thereafter, there was a steady decline in both generalist and rheumatologist visits. One hundred forty-four (40%) patients had no rheumatologist visits and 102 (28%) had only 1 rheumatologist visit, mostly for diagnostic confirmation. Men and patients with several comorbid conditions were significantly more likely to be seen by rheumatologists (P < 0.001). However, once referred, women, older patients, and those with GCA, PMR relapses, and corticosteroid complications had significantly more rheumatologist visits (P < 0.001).
CONCLUSION: The use of physician services in PMR is considerable. Generalists provide the large majority of care. Rheumatologist involvement is generally limited to diagnostic confirmation and management of complications. The relative paucity of rheumatology care following the period of diagnosis may represent an opportunity for improving the care of patients with PMR.

Entities:  

Mesh:

Year:  2005        PMID: 15934100     DOI: 10.1002/art.21160

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

Review 1.  Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Authors:  Michael Schirmer; Christian Dejaco; Bhaskar Dasgupta; Eric L Matteson
Journal:  Rheumatol Int       Date:  2015-06-02       Impact factor: 2.631

Review 2.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.

Authors:  Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

Review 3.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

4.  Lack of association of high body mass index with risk for developing polymyalgia rheumatica.

Authors:  Deana D Hoganson; Cynthia S Crowson; Kenneth J Warrington; Sherine E Gabriel; Eric L Matteson
Journal:  Int J Rheum Dis       Date:  2010-08       Impact factor: 2.454

5.  The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.

Authors:  Sarah L Mackie; Helen Twohig; Lorna M Neill; Eileen Harrison; Beverley Shea; Rachel J Black; Tanaz A Kermani; Peter A Merkel; Christian D Mallen; Frank Buttgereit; Chetan Mukhtyar; Lee S Simon; Catherine L Hill
Journal:  J Rheumatol       Date:  2017-08-01       Impact factor: 4.666

Review 6.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

7.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

8.  The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan.

Authors:  Toshikatsu Okumura; Satoshi Tanno; Masumi Ohhira; Tsukasa Nozu
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

9.  Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice.

Authors:  Toby Helliwell; Sara Muller; Samantha L Hider; Irena Zwierska; Sarah Lawton; Jane Richardson; Christian Mallen
Journal:  Br J Gen Pract       Date:  2018-11       Impact factor: 5.386

10.  Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice.

Authors:  Toby Helliwell; Samantha Lara Hider; Christian David Mallen
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.